Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Feature Reviews in Precision Oncology
share announcement

Feature Reviews in Precision Oncology

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (28 February 2025) | Viewed by 3281

Special Issue Editor

Dr. Luca Filippi

E-Mail Website
Guest Editor
Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Viale Oxfors 81, 00133 Rome, Italy
Interests: FDG PET/CT; oncology; therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Precision oncology represents a transformative approach to cancer treatment that tailors therapeutic strategies to the individual characteristics of each patient. This field integrates advanced genomic and molecular profiling in the laboratory with cutting-edge imaging techniques to identify and target the specific features of a patient’s cancer.

We are pleased to invite you to contribute to our upcoming Special Issue entitled “Feature Reviews in Precision Oncology”. This Special Issue will focus exclusively on comprehensive review articles that provide critical insights into the latest advancements and challenges in precision oncology.

The Special Issue aims to gather authoritative reviews that cover a broad spectrum of topics within precision oncology, including, but not limited to, the following:

  • Advances in genomic and molecular profiling;
  • Targeted therapies and immunotherapies;
  • Molecular imaging and theranostics;
  • Biomarker discovery and validation;
  • Personalized treatment strategies;
  • Emerging technologies and methodologies in cancer research.

Your expertise and insights would be a valuable addition to this collection. We encourage you to submit a review article that addresses key developments, current trends, and future directions in your area of research.

Please note that this Special Issue will only accept review articles, not original research papers.

We look forward to your contribution and to shaping a comprehensive resource that will serve the precision oncology community.

Dr. Luca Filippi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer treatment
  • genomic and molecular profiling
  • targeted therapies and immunotherapies
  • molecular imaging and theranostics
  • biomarker discovery and validation
  • personalized treatment strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

25 pages, 3231 KiB  
Review
Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review
by Nigel P. Murray
Biomedicines 2025, 13(5), 1179; https://doi.org/10.3390/biomedicines13051179 - 12 May 2025
Abstract
Immunotherapy alone or in combination with chemotherapy or radiotherapy is the frontline treatment for melanoma and lung cancer. However, its role in prostate cancer is usually as a fourth-line treatment. It is usually employed in patients with metastasis, after androgen blockade and chemotherapy. [...] Read more.
Immunotherapy alone or in combination with chemotherapy or radiotherapy is the frontline treatment for melanoma and lung cancer. However, its role in prostate cancer is usually as a fourth-line treatment. It is usually employed in patients with metastasis, after androgen blockade and chemotherapy. This article reviews the immunosuppressive effects of prostate cancer and possible uses of various types of immunotherapies. It also considers when would be the optimal time to employ this type of therapy. Full article
(This article belongs to the Special Issue Feature Reviews in Precision Oncology)
►▼ Show Figures

Figure 1

17 pages, 2058 KiB  
Review
Targeting Metabolic Reprogramming in Bladder Cancer Immunotherapy: A Precision Medicine Approach
by Fuyang Liu, Kai Li and Qingyi Zhu
Biomedicines 2025, 13(5), 1145; https://doi.org/10.3390/biomedicines13051145 - 9 May 2025
Viewed by 247
Abstract
Bladder cancer, as a highly heterogeneous malignant tumor of the urinary system, is significantly affected by tumor metabolic reprogramming in its response to immunotherapy. This review systematically elaborates on the molecular mechanisms of abnormal glucose and lipid metabolism in the bladder cancer microenvironment [...] Read more.
Bladder cancer, as a highly heterogeneous malignant tumor of the urinary system, is significantly affected by tumor metabolic reprogramming in its response to immunotherapy. This review systematically elaborates on the molecular mechanisms of abnormal glucose and lipid metabolism in the bladder cancer microenvironment and immune escape, and discusses precision treatment strategies based on metabolic regulation. In the future, it will be necessary to combine spatiotemporal omics and artificial intelligence technologies to construct a multi-target intervention system for the metabolic–immune interaction network, promoting a paradigm shift in precision treatment for bladder cancer. Full article
(This article belongs to the Special Issue Feature Reviews in Precision Oncology)
►▼ Show Figures

Figure 1

31 pages, 1798 KiB  
Review
Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
by Jeong Uk Lim, Junyang Jung, Yeon Wook Kim, Chi Young Kim, Sang Hoon Lee, Dong Won Park, Sue In Choi, Wonjun Ji, Chang Dong Yeo and Seung Hyeun Lee
Biomedicines 2025, 13(2), 470; https://doi.org/10.3390/biomedicines13020470 - 14 Feb 2025
Cited by 1 | Viewed by 1662
Abstract
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. However, treatment resistance remains a major challenge in clinical practice. The tumor microenvironment (TME) is a complex system composed of tumor cells, immune and non-immune [...] Read more.
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. However, treatment resistance remains a major challenge in clinical practice. The tumor microenvironment (TME) is a complex system composed of tumor cells, immune and non-immune cells, and non-cellular components. Evidence indicates that dynamic changes in TME during TKI treatment are associated with the development of resistance. Research has focused on identifying how each component of the TME interacts with tumors and TKIs to understand therapeutic targets that could address TKI resistance. In this review, we describe how TME components, such as immune cells, fibroblasts, blood vessels, immune checkpoint proteins, and cytokines, interact with EGFR-mutant tumors and how they can promote resistance to TKIs. Furthermore, we discuss potential strategies targeting TME as a novel therapeutic approach. Full article
(This article belongs to the Special Issue Feature Reviews in Precision Oncology)
►▼ Show Figures

Figure 1

20 pages, 651 KiB  
Review
The Tight Relationship Between the Tumoral Microenvironment and Radium-223
by Miriam Conte, Miriam Tomaciello, Maria Silvia De Feo, Viviana Frantellizzi, Francesco Marampon, Flaminia De Cristofaro, Giuseppe De Vincentis and Luca Filippi
Biomedicines 2025, 13(2), 456; https://doi.org/10.3390/biomedicines13020456 - 12 Feb 2025
Viewed by 860
Abstract
Radium-223 (223Ra) was the first radioactive isotope approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without visceral metastatic disease. To better understand the action of 223Ra, its role in the tumor microenvironment represents a crucial aspect. A [...] Read more.
Radium-223 (223Ra) was the first radioactive isotope approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without visceral metastatic disease. To better understand the action of 223Ra, its role in the tumor microenvironment represents a crucial aspect. A literature search was conducted using the PubMed/MEDLINE database and studies regarding the relationship between 223Ra and the tumoral microenvironment were considered. The tumoral microenvironment is a complex setting in which complex interactions between cells and molecules occur. Radium-223, as an alpha-emitter, induces double-stranded DNA breaks; to potentiate this effect, it could be used in patients with genetic instability but also in combination with therapies which inhibit DNA repair, modulate the immune response, or control tumor growth. In conclusion, a few studies have taken into consideration the tumoral microenvironment in association with 223Ra. However, its understanding is a priority to better comprehend how to effectively exploit 223Ra and its action mechanism. Full article
(This article belongs to the Special Issue Feature Reviews in Precision Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop